Deamidated gliadin peptide (DGP) is the essential diagnostic antigen because the pathogenic autoimmune response in celiac disease is triggered exclusively by the deamidated form of gliadin, not the intact native protein.
Immunoassays built with native gliadin detect a broad, non-specific antibody pool that includes many clinically irrelevant cross-reactivities, resulting in poor specificity and unreliable patient identification.
Switching to deamidated gliadin as the solid‑phase antigen directly captures the disease‑relevant antibodies, delivering a simultaneous leap in both clinical sensitivity and diagnostic specificity—a critical achievement for any screening or monitoring kit.
The root cause of celiac disease is the T‑cell recognition of gliadin peptides only after they have been deamidated by tissue transglutaminase.
A diagnostic kit that ignores this central pathogenic mechanism is measuring noise; a kit that embraces it by using DGP provides a signal that is directly linked to disease activity. This is the single most important design decision for a reliable serological assay.
The Pathological Driver of Celiac Disease
T-Cell Activation Requires Deamidated Gliadin
Celiac disease is an HLA‑linked autoimmune disorder.
The disease‑causing T‑cells are restricted to the HLA‑DQ2 or HLA‑DQ8 molecules, and they only recognize gliadin when specific glutamine residues have been converted to glutamic acid.
This deamidation is performed in vivo by tissue transglutaminase, creating the negatively charged epitopes that stably bind into the HLA pocket.
Without deamidation, the native gliadin peptides simply do not fit the MHC‑T‑cell receptor interface properly.
The pathogenic cascade—T‑cell help to B‑cells, production of high‑affinity autoantibodies—never fires without that structural change.
Intact Native Gliadin Measures an Irrelevant Antibody Spectrum
Most people produce low‑avidity IgM or IgG antibodies against various dietary proteins, including native gliadin.
These antibodies are physiological and carry no association with active celiac disease.
When a kit uses intact native gliadin as the capture antigen, it detects this entire background pool, leading to unacceptable false‑positive rates.
In contrast, the clinically relevant autoantibodies that develop in celiac patients are heavily biased toward recognizing deamidated epitopes that cross‑link with tissue transglutaminase.
Thus, an antigen based on native gliadin is measuring the wrong thing—a fundamental misalignment with disease biology that undermines the entire test.
How Antigen Choice Transforms Assay Performance
Specificity: Closing the Gate on False Positives
Conventional native gliadin assays often suffer from specificity as low as 50–60% in some cohorts, making them unusable for population screening.
DGP‑based assays, especially those detecting IgG antibodies, flip this picture: DGP‑IgG specificity reaches approximately 99%, on par with the gold‑standard tissue transglutaminase IgA test.
This specificity gain means fewer diagnostic uncertainties, fewer unnecessary intestinal biopsies, and far greater clinician confidence in the result.
For the manufacturer, it directly translates into a product that can be marketed as a definitive diagnostic aid rather than a mere screening tool.
Sensitivity: Capturing the Full Pathogenic Response
The deamidated antigen not only eliminates irrelevant signals but also uncovers higher‑affinity antibody interactions that native gliadin misses.
DGP‑IgA assays show clinical sensitivity in the range of 85–90%, comparable to the best available serological markers, while DGP‑IgG maintains strong sensitivity even in the presence of IgA deficiency.
Crucially, using DGP ensures that the test remains accurate in high‑risk groups—type 1 diabetes, autoimmune thyroid disease, and selective IgA deficiency—where misdiagnosis carries particularly severe clinical consequences.
The antigen’s conformation presents the epitopes in a way that mirrors the in vivo immune complex, so the antibodies bind with high avidity and produce robust assay signals.
Practical Considerations and Trade‑offs
The Art and Science of Deamidation
Not all “deamidated gliadin” preparations are equal.
If the deamidation process is incomplete or heterogeneous, the antigen surface will still display native‑like patches that attract non‑specific antibodies, undercutting the specificity advantage.
Manufacturers must invest in precisely controlled enzymatic or chemical deamidation and rigorous lot‑to‑lot characterization.
The use of high‑purity, standardized DGP raw materials is non‑negotiable—any deviation introduces cross‑reactivity and compromises the diagnostic accuracy the market demands.
The IgA‑Deficiency Trap
Selective IgA deficiency occurs in approximately 1 in 600 individuals and is over‑represented among celiac patients.
A kit that relies exclusively on DGP‑IgA will generate false‑negative results in these individuals, who logically need an IgG‑based companion test.
While DGP‑IgG offers outstanding specificity, its sensitivity is slightly lower than DGP‑IgA in IgA‑competent populations.
The trade‑off is mitigated by offering a dual‑isotype kit or a reflex testing algorithm, but the manufacturing complexity and cost increase.
The antigen itself, however, remains the same—deamidated gliadin peptides work beautifully for both antibody classes, preserving the core analytical advantage.
Making the Right Choice for Your Immunoassay Development
The decision to use deamidated gliadin peptide is not a nuance—it is the foundation of a medically credible product.
The specific format and antibody class, however, should be tailored to your intended clinical use case.
- If your primary focus is screening the general population: Implement a DGP‑IgA assay combined with a DGP‑IgG reflex or a parallel dual‑isotype test. The near‑perfect specificity of DGP‑IgG drastically reduces false positives, while the high sensitivity of DGP‑IgA prevents missed cases.
- If your primary focus is testing patients with known IgA deficiency or associated autoimmune conditions: Prioritize the DGP‑IgG assay as the front‑line marker. Its ~99% specificity and robust performance in this vulnerable group make it an ethically and clinically sound choice, eliminating the risk of IgA‑dependent false negatives.
- If your primary focus is monitoring adherence to a gluten‑free diet: Use DGP‑IgA as the monitoring marker, as its levels correlate well with gluten withdrawal and reintroduction. The DGP antigen provides a sharper dynamic range than native gliadin, allowing you to detect dietary lapses early.
Building your assay around deamidated gliadin peptide aligns your diagnostic kit with the molecular truth of the disease. That alignment is what turns a laboratory reagent into a tool that clinicians can trust to change patient lives.
Summary Table:
| Feature / Parameter | Native Intact Gliadin | Deamidated Gliadin Peptide (DGP) |
|---|---|---|
| Biological Relevance | Detects non-specific dietary antibodies | Targets disease-causing, HLA-restricted T-cell epitopes |
| Diagnostic Specificity | Low (50%–60%, high false-positive rate) | Excellent (~99% for DGP-IgG) |
| Diagnostic Sensitivity | Inconsistent | High (85%–90% for DGP-IgA) |
| IgA Deficiency Utility | Unreliable | Highly reliable with DGP-IgG companion assays |
| Assay Application | Outdated screening | Definitive screening, monitoring & diagnostic aid |
Elevate Your Immunoassay Performance with Quality DGP Raw Materials
Developing high-precision diagnostic kits requires uncompromising raw material quality. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you need ultra-pure Deamidated Gliadin Peptide antigens or technical support to eliminate non-specific binding, we are here to support your assay development. Contact us today to request product samples or consult with our technical experts!